Browsing Tag
GLP-1
50 posts
Novo Nordisk advances amycretin to phase 3 after early data show weight loss of up to 24% in obesity trials
Novo Nordisk moves amycretin to phase 3 after early trials show up to 24% weight loss. See what makes this dual-receptor drug a next-gen obesity contender.
Novo Nordisk’s high-dose Wegovy delivers 21% weight loss in STEP UP Phase 3 trial results
Novo Nordisk’s high-dose Wegovy led to 21% weight loss in a Phase 3 trial. Learn what the STEP UP data means for obesity care and future regulatory plans.
Can Lilly’s flat $499/month Zepbound pricing reshape obesity drug access in the U.S.?
Lilly expands Zepbound access via LillyDirect, offering all FDA-approved doses for $499/month. Explore the implications for patients and the GLP-1 drug market.
LifeVantage stock in 2025: Riding the GLP-1 wave or facing a reality check?
LifeVantage stock cools after its GLP-1 rally — but is the growth story still intact? Here’s a fresh look at LFVN’s financials, momentum, and investor outlook.
Hims & Hers Health soars over 10% after Wegovy rollout, Q1 strength, and analyst upgrades
Hims & Hers Health stock jumped 10.36% on May 16, 2025, after a Wegovy rollout, strong Q1 earnings, and analyst upgrades boosted investor confidence.
Palatin Technologies completes Phase 2 obesity trial with MC4R bremelanotide and GLP-1/GIP tirzepatide
Palatin Technologies, Inc. has announced the completion of its Phase 2 BMT-801 clinical trial, a study evaluating the…
OneSource Specialty Pharma reports stellar Q3FY25 earnings with 85% EBITDA growth, setting stage for expansion
OneSource Specialty Pharma Limited, formerly Stelis Biopharma Limited, has delivered a strong financial performance in its first full…
Eli Lilly’s stock plummets over missed sales forecasts for Mounjaro, Zepbound – what’s next for the pharma giant?
Eli Lilly & Co. has faced a dramatic drop in its stock price, tumbling over 10% following a…
Biocon joins forces with Tabuk Pharmaceuticals to bring GLP-1 diabetes drugs to Middle East
In a strategic move to tackle the growing diabetes crisis in the Middle East, Biocon Limited has announced…
LifeVantage stock soars on game-changing GLP-1 study results – here’s what you need to know
Shares of LifeVantage Corporation have jumped 8.2% after the company announced encouraging results from a study on its…